Urovant Sciences Ltd. announced earnings results for the third quarter ended December 31, 2020. For the third quarter, the company announced net loss was USD 46.797 million compared to USD 41.259 million a year ago. Basic loss per share from continuing operations was USD 1.46 compared to USD 1.36 a year ago. For the nine months, net loss was USD 112.447 million compared to USD 95.485 million a year ago. Basic loss per share from continuing operations was USD 3.59 compared to USD 3.14 a year ago.